Competitor Analysis c-Met/HGF Inhibitors

• Publication date: February 2010

Product description The Competitive Intelligence Report c-MET/HGF Inhibitors as of February 2010 provides a competitor analysis in the development pipeline of novel emerging inhibitors of c-MET receptor tyrosine kinase (RTK) and its ligand hepatocyte growth factor (HGF) or scatter factor (SF) for treatment of solid tumors. Most of the inhibitors are small molecules, but antibodies are a strongly emerging class of c-Met/HGF antagonis...

Product description

The Competitive Intelligence Report c-MET/HGF Inhibitors as of February 2010 provides a competitor analysis in the development pipeline of novel emerging inhibitors of c-MET receptor tyrosine kinase (RTK) and its ligand hepatocyte growth factor (HGF) or scatter factor (SF) for treatment of solid tumors. Most of the inhibitors are small molecules, but antibodies are a strongly emerging class of c-Met/HGF antagonists.

The c-MET signalling pathway consists of the mesenchymal epithelial transition factor (c-MET) transmembrane tyrosine kinase receptor and its ligand hepatocyte growth factor (HGF) or scatter factor (SF). Binding of HGF/SF to c-MET activates downstream signalling pathways such as Rho, focal adhesion kinase (FAK) and PI3K. These pathways regulate cancer cell growth, survival angiogenesis, invasion and metastasis. Thus, prevention of c-MET dependent neoplastic processes may provide a means for managing invasive tumors of high metastatic potential. In fact, c-MET/HGF has evolved as an attractive target for the pharmaceutical industry.

At present, at least 16 different molecules including four antibodies are in clinical development and quite a number of projects are in preclinical development. The majority of approaches are directed at inhibiting the c-MET receptor tyrosine kinsase (RTK) by small molecules. The first generation of c-MET RTK inhibitors are dual- or multi-targeting c-MET inhibitors. These multi-target c-MET inhibitors are most advanced in clinical development with two projects in phase III. The next wave of c-MET inhibitors typically are ATP-competitive potent and highly selective c-MET inhibitors with lead compounds in phase II.

The Competitor Analysis c-MET/HGF Inhibitors also provides the corporate R&D pipelines for c-MET/HGF Inhibitors. The report includes a compilation of current active projects in research and development of c-Met/HGF Inhibitors. Competitor projects are listed in a tabular format providing Information on:

* Drug Codes,
* Target / Mechanism of Action,
* Class of Compound,
* Company,
* Product category,
* Indication,
* R&D Stage and
* additional comments with a hyperlink leading to the source of information.

Index

* Selective c-MET/HGF Inhibitors
* Dual- and Multi-Targeting c-MET/HGF Inhibitors
* C-Met/HGF Inhibitory Antibodies

Drug Discovery And Development Industry